Introduction

What is known?
Previous studies have shown that combination treatment with umeclidinium (UMEC)/ vilanterol (VI) improves lung function compared with monotherapies, and the tolerability and safety of UMEC/VI has also been studied. However, few patients in these studies were Asian, and specific subanalyses of these populations were not carried out. 1 LAMAs inhibit muscarinic receptors in the airways and block cholinergic bronchoconstriction, thereby decreasing airway smooth-muscle contraction. 6 The complementary mechanisms of bronchodilatory action of coadministered LAMAs and LABAs leads to improvements in lung function in patients with COPD compared with LAMA or LABA monotherapy. [6] [7] [8] [9] LAMA/LABA combination therapy may also decrease the risk of side effects when compared with dose escalation of LAMA and LABA monotherapies, 1 and has the potential to offer improved convenience over monotherapies and subsequently improve treatment compliance.
The combination of the inhaled LAMA UMEC with the LABA VI is an approved maintenance treatment for COPD in the US and EU. 9 Previous studies in predominantly Western populations have provided evidence for the efficacy of UMEC/VI 125/25 μg and 62.5/25 μg as maintenance therapy in the treatment of moderate-very severe COPD. 6, 9, 10 As interethnic differences are known to exist for some drug classes, the characterization of the efficacy and safety profile of inhaled UMEC/VI in patients with COPD of Asian ancestry is warranted. This study evaluated the efficacy and safety of UMEC/VI 125/25 μg and 62.5/25 μg administered once daily over 24 weeks in patients of Asian ancestry with COPD.
Patients and methods
Study design
This was a 24-week, Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study (ClinicalTrials.gov identifier NCT01636713, GSK study DB2114634) of once-daily UMEC/VI 125/25 μg and 62.5/25 μg conducted in mainland People's Republic of China, Philippines, South Korea, Taiwan, and Thailand.
Patients
Eligible patients were male or female, 40 years of age at screening, with an established clinical history of COPD, as defined by the American Thoracic Society/European Respiratory Society criteria. 11 Patients were also current or former smokers with a smoking history 10 pack-years; had a postalbuterol forced expiratory volume in 1 second (FEV 1 )/forced vital capacity (FVC) ratio of 0.70 and a postalbuterol FEV 1 70% of predicted normal values (based on National Health and Nutrition Examination Survey III reference equations at visit 1), 12, 13 and a dyspnea score of 2 on the modified Medical Research Council Dyspnea Scale at screening. Patients were excluded if they had a current diagnosis of asthma or any other known respiratory disorder, including α 1 -antitrypsin deficiency or active lung infection, eg, tuberculosis, lung cancer, clinically significant bronchiectasis, pulmonary hypertension, sarcoidosis, or interstitial lung disease. Patients with a previous history or current evidence of clinically significant or uncontrolled cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine, or hematological abnormalities were also excluded. A full list of inclusion and exclusion criteria is detailed in the Supplementary materials.
Written informed consent was obtained from each patient prior to the performance of any study-specific procedure. This study was conducted in accordance with International Conference on Harmonisation Good Clinical Practice and all applicable subject privacy requirements, and the ethical principles that are outlined in the Declaration of Helsinki 2008. This study was approved by the Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University and other local ethics committees.
GlaxoSmithKline using the validated computerized system RandAll version 2.5. All randomized study medication was delivered via dry-powder inhalers each morning.
All patients received supplemental albuterol (metereddose inhaler and/or nebules) to be used as rescue medication throughout the study. The use of inhaled corticosteroid was permitted provided the dose did not exceed 1,000 μg of fluticasone propionate or equivalent per day, and the inhaled corticosteroid was not initiated or discontinued within 30 days prior to study entry.
Investigational product taken during the 24-week treatment period was administered in a double-blind fashion. Neither the subject nor the study physician knew which study medication the subject was receiving.
Study outcomes Lung-function end points
The primary efficacy end point was trough FEV 1 on day 169 (defined as the mean of the FEV 1 values obtained at 23 and 24 hours after the dose administered on day 168). The secondary lung-function end point was weighted mean (WM) FEV 1 over 0-6 hours after dosing on day 1. Other lung-function end points included trough FEV 1 at other time points; serial FEV 1 over 0-6 hours postdose at day 1; the proportion of patients achieving an increase in FEV 1 of 12% and 0.200 L above baseline at any time 0-6 hours postdose on day 1; the proportion of patients achieving an increase of 0.100 L above baseline in trough FEV 1 ; and trough and serial FVC and time to onset (defined as an increase of 0.100 L in FEV 1 above baseline) 0-6 hours postdose at day 1.
Symptomatic end points
Symptomatic end points included Transition Dyspnea Index (TDI) focal score at week 24 (which was a secondary end point in this study), TDI focal score recorded at other time points, and proportion of TDI responders (a responder to TDI was defined as a patient who reported a TDI score of 1 unit). Additional symptomatic end points were rescue-albuterol use (percentage of rescue-free days and puffs/day) and time to first COPD exacerbation (defined as an acute worsening of symptoms of COPD requiring the use of rescue albuterol or any treatment beyond study medication).
Health-related QoL assessments
Health-related QoL (HRQoL) was measured by the St George's Respiratory Questionnaire (SGRQ), COPD assessment test (CAT), and a COPD-related health care resource-utilization assessment. Further information on HRQoL assessments is detailed in the Supplementary materials.
Safety assessments
Safety assessments included the incidence of adverse events (AEs) and serious AEs (SAEs), vital signs (including pulse rate and systolic and diastolic blood pressure), 12-lead electrocardiogram (ECG) parameters, and clinical chemistry and hematology parameters (including routine urinalysis). AEs and SAEs were recorded from visit 2 (study-treatment start) until visit 9 (follow-up). Any SAEs assessed as related to study participation (eg, study treatment, protocol-mandated procedures, invasive tests, or change in existing therapy) or related to a GlaxoSmithKline concomitant medication, were recorded from the time informed consent was given up to and including any follow-up contact.
Statistical analysis
Sample size was calculated based on the primary end point of trough FEV 1 on day 169 and assumed 90% power, and a two-sided 5% significance level. Furthermore, an estimate of residual standard deviation (SD) of 0.240 L was calculated, in addition to a treatment difference from any UMEC/VI group and placebo of 0.100 L. Based upon these assumptions, 123 evaluable subjects were required for each treatment arm. However, this was increased to 191 evaluable subjects per arm, in order to meet individual country and regional requirements and account for an estimated 21% withdrawal rate over the 24-week study period. Primary analyses were performed on the intent-to-treat (ITT) population, defined as all patients randomized to treatment who had received at least one dose of randomized study medication during the treatment period. For the primary end point of trough FEV 1 on day 169, mixed model for repeated measures (MMRM) analysis was performed with all available postbaseline assessments for subjects in the ITT population, including the following covariates: baseline FEV 1 (mean of the two assessments made 30 and 5 minutes predose on day 1), smoking status, day, country/region, treatment, day-bybaseline interaction and day-by-treatment interaction, where "day" was nominal. Analysis of mean TDI focal score on days 28, 84, and 168 used MMRM analysis with Baseline Dyspnea Index score in place of the baseline FEV 1 . WM clinic visit FEV 1 over 0-6 hours postdose was analyzed using analysis of covariance with baseline FEV 1 (mean of the two assessments made 30 and 5 minutes predose on day 1), treatment, smoking status, and country/region as covariates. Time to onset of bronchodilation and time to first COPD exacerbation were analyzed using Cox's proportional hazard model with covariates of treatment, smoking status, and country/region. 
Results
Study population
Of the 739 patients screened, a total of 580 patients were enrolled from July 16, 2012 to October 25, 2013 and included in the ITT population. The majority of patients (n=497 [86%]) completed the study (Figure 1 
Efficacy -lung function
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Duration of COPD, n (%)
1 year 40 (21) 45 (23) 47 (24) 132 (23) 1 to 5 years 93 (48) 82 (42) 85 (44) 260 (45) 5 to 10 years 37 (19) 39 (20) 32 (17) 108 (19) 10 to 15 years 14 (7) 20 (10) 22 (11) 56 (10) 15 to 20 years 5 (3) 3 (2) 2 (1) 10 (2) 20 to 25 years 3 (2) 3 (2) 2 (1) 8 (1) 25 years 1 (1) 2 (1) 3 (2) 6 (1) GOLD stage, n (%) Other COPD medication 21 (11) 13 (7) 21 (11) 55 (9) Cold, cough, nasal, and/or throat medication 13 (7) 12 (6) 11 (6) 36 (6) Short-acting anticholinergic 6 (3) 14 (7) 11 (6) 
Efficacy -symptoms
Clinically meaningful improvements in TDI score (defined as a TDI score of 1 unit) were observed for both UMEC/VI doses at day 168 and both other days assessed (day 28 and day 84). Furthermore, TDI scores for the UMEC/VI treatment groups were statistically significantly greater compared with placebo at day 168 (UMEC/VI 125/25 μg, 0.9, 95% CI 0.3-1.4, P=0.002; UMEC/VI 62.5/25 μg, 0.7, 95% CI 0.1-1.2, P=0.016) ( Table 2 ). The treatment differences for both UMEC/VI 62.5/25 and 125/25 μg versus placebo were also statistically significant at days 28 and 84 (P0.001 for both treatments (Figure 4 ). Patients receiving UMEC/VI also had statistically significantly higher odds of being a TDI responder compared with placebo at all time points assessed, except for day 168 with UMEC/VI 62.5/25 μg (day 168: OR UMEC/VI 125/25 μg, 1.6, 95% CI 1.1-2.5, P=0.022; UMEC/VI 62.5/25 μg, 1.3, 95% CI 0.9-2.1, P=0.163) ( Table 2) . Rescue-medication use (puffs/day) was statistically significantly reduced with UMEC/VI compared with placebo (UMEC/VI 125/25 μg, -0.7, 95% CI -0.9 to -0.4; UMEC/VI 62.5/25 μg, -0.6, 95% CI -0.9 to -0.4; P0.001 for both), while the percentage of rescue-free days over weeks 1-24 was greater for UMEC 125/25 μg (67.8%) and UMEC 62.5/25 μg (64.0%) compared with placebo (48.6%).
On-treatment COPD exacerbations were reported by more patients receiving placebo (17%) compared with UMEC/VI 125/25 μg and 62.5/25 μg (7% and 10%, respectively). Analysis of time to first COPD exacerbation found that UMEC/VI 125/25 μg also reduced the risk of COPD exacerbation compared with placebo, but not for UMEC/VI 62. 
Health-related QoL
UMEC/VI was associated with statistically significant reductions in SGRQ total score that were approximate to the minimal clinically important reduction of 4 units 14 at all time points for UMEC/VI 125/25 μg and at day 84 for UMEC/VI 62.5/25 μg compared with placebo (see Table S2 for data). Furthermore, patients treated with UMEC/VI had higher odds of being an SGRQ responder (defined as a 4-unit decrease from baseline) at day 168 relative to placebo (UMEC/VI 125/25 μg, OR 1.8, 95% CI 1.1-2.7, P=0.010; UMEC/VI 62.5/25 μg, OR 1.5, 95% CI 1.0-2.4, P=0.045) ( Table 2 ). Clinically meaningful improvements from baseline in mean CAT scores were observed for both UMEC/VI treatment groups at day 168 (UMEC/VI 125/25 μg, -3.54, 
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Efficacy and safety of UMEC/VI in Asian patients with COPD minimum-maximum -27.0 to 17.0, SD =6.386; UMEC/VI 62.5/25 μg, -3.24, minimum-maximum -21.0 to 16.0, SD =6.488). The proportion of patients who reported unscheduled health care utilization was low (1%-2% across treatment groups).
Safety
The incidence of AEs was similar across treatment groups (placebo, 39%; UMEC/VI 125/25 μg, 34%; UMEC/VI 62.5/25 μg, 34%); nasopharyngitis and upper respiratory tract infection were the most common AEs across the treatment groups (Table 3 ). AEs associated with antimuscarinic effects, such as dry mouth and urinary retention, were low and similar across UMEC/VI treatment groups and placebo. Overall, the incidence of drug-related AEs was low across both UMEC/VI treatment groups (UMEC/VI 125/25 μg, 5%; UMEC/VI 62.5/25 μg, 4%) and similar to placebo (5%).
There was a low incidence of cardiovascular AEs of special interest (2%-6%) and pneumonia and lower respiratory tract infections (as an AE of special interest, 2%-3%) across treatment groups. On-treatment nonfatal SAEs reported by 1% of patients in any treatment group were COPD (placebo, 5%; UMEC/VI (9) 16 (8) 7 (4) Any on-treatment nonfatal SAE 17 (9) 14 (7) 5 (3) Any posttreatment nonfatal SAE 1 (1) 0 0 Any on-treatment drug-related nonfatal SAE 1 (1) 1 (1) 0 Any drug-related fatal SAE 0 0 1 (1) Any fatal SAE 0 1 (1) 1 (1) AE reported by 3% of patients in any treatment group, n (%) Nasopharyngitis 18 (9) 17 (9) 18 (9) Upper respiratory tract infection 11 (6) 19 (10) 13 (7) Chronic obstructive pulmonary disease 9 (5) 9 (5) 3 (2) Cough 4 (2) 6 (3) 4 (2) On-treatment AEs of special interest, b n (%) Any cardiovascular event 6 (3) 3 (2) 11 (6) Anticholinergic events, n (%) Dry mouth 3 (2) 1 (1) 4 (2) Urinary retention 0 0 1 (1)
Notes:
a Includes both on-treatment and posttreatment AEs; b incidence of AEs of special interest comprised of events in selected Standardised MedDRA Queries (SMQs) and/or individual preferred terms (PTs). Cardiovascular AEs of special interest comprised SMQs for cardiac arrhythmias, cardiac failure, cardiac ischemia (myocardial infarction, other ischemic heart disease), and stroke (central nervous system hemorrhages and cerebrovascular conditions). Anticholinergic AEs of special interest comprised terms in the anticholinergic syndrome SMQs. Urinary retention comprised PTs of urinary retention, urinary hesitation, decreased micturition frequency, decreased urine flow, and Fowler's syndrome. Abbreviations: AE, adverse event; ITT, intent-to-treat; SAE, serious AE; UMEC, umeclidinium; VI, vilanterol.
125/25 μg, 1%; UMEC/VI 62.5/25 μg, 5%) and pneumonia (placebo, 1%; UMEC/VI 125/25 μg, 1%; UMEC/VI 62.5/25 μg, 1%). Two deaths occurred during the study. One patient in the UMEC/VI 125/25 μg group had acute respiratory failure, COPD, pneumonia, and septic shock, which was considered to be treatment-related by the study investigator. One patient in the UMEC/VI 62.5/25 μg group died of drowning, which was not considered to be treatment-related. There were no clinically-meaningful effects on vital signs, ECGs, or clinical chemistry and hematology parameters.
Discussion
This study aimed to examine the efficacy and safety of oncedaily inhaled UMEC/VI 125/25 μg and 62.5/25 μg in patients of Asian ancestry with COPD over a 24-week period. In this previously unstudied population, treatment with once-daily UMEC/VI 125/25 μg and UMEC/VI 62.5/25 μg resulted in clinically meaningful improvements in lung-function measurements compared with placebo over a 24-week period.
In addition to improvements in lung function, there was evidence of symptomatic improvement with both UMEC/VI treatment doses, with statistically significant improvements in focal TDI score and a suggested benefit on the frequency of COPD exacerbations. The improvements in lung function and COPD symptoms had additional benefits on QoL parameters, with improvements observed in SGRQ and CAT scores.
These observations are generally consistent with the results of previous studies in predominantly Caucasian patients with COPD, which also reported lung-function improvements, symptom improvements, and improvements in HRQoL with once-daily UMEC/VI. [6] [7] [8] [9] [10] 15 In one such study, trough FEV 1 (primary end point) was statistically significantly improved at day 169 for UMEC/VI 62.5/25 μg compared with placebo (difference of 0.167, 95% CI 0.128-0.207 L). 6 Similarly, improvements in trough FEV 1 and from 1.8 to 2.9 for UMEC 125/25 μg. 7, 8 Change from baseline in rescue use (puffs/day) and SGRQ total score ranged from -1.3 to -2.7 and -7.27 to -9.95, respectively, with UMEC 62.5/25 μg, 6, 8, 15 and from -2.2 to -2.7 and -3.6 to -9.95, respectively, with UMEC 125/25 μg.
7,8
The safety profile of UMEC/VI was similar to that previously reported in Caucasian patients with COPD, with headache, nasopharyngitis, extrasystoles, upper respiratory tract infection, cough, and back pain being the most commonly reported AEs. [6] [7] [8] 10, 15 Both doses of UMEC/VI appeared to be well tolerated, with no notable treatment-related changes in vital signs, ECGs, or clinical laboratory parameters, and no new safety concerns were raised.
The efficacy and safety profile of UMEC/VI in Asian patients with COPD therefore appears to be consistent with previous studies in predominantly Western COPD patient populations, 6, 8, 10 suggesting that ethnicity is not a factor of variance in response to UMEC/VI treatment.
Studies of other LABA/LAMA dual bronchodilators, such as QVA149 (indacaterol and glycopyrronium), have also reported benefits in patients with COPD; however, comparisons with such studies cannot be made, due to differences in study populations and design. In addition, these studies were also carried out in predominantly Caucasian populations (approximately 20%-30% of patients were Asian), and specific subanalyses for race were not reported. 16, 17 Similarly, a combination of olodaterol and tiotropium has been shown to provide additional improvements in lung function compared with tiotropium alone, but specific Asian subanalyses have not been reported. 18 A limitation of the present study was that although the baseline characteristics were generally balanced across the treatment groups, there was a higher percentage of patients with GOLD stage IV COPD in patients receiving UMEC/VI 62.5/25 μg (18%) compared with placebo (13%) and UMEC/VI 125/25 μg (11%). This could explain why there were greater differences in the lung-function response observed between the two UMEC/VI doses than was observed in other studies. 8 A large placebo response was also observed in the TDI responder analysis. The reason for this is unknown, but a similar placebo effect has been observed in a previous placebo-controlled UMEC/VI study 6 and another COPD trial conducted with patients of Asian heritage. 19 Findings from the present study suggested a beneficial effect on the frequency of COPD exacerbations; however, it should be noted that this study was not specifically designed to evaluate the effects of UMEC/VI on COPD exacerbations, thereby limiting the interpretation of these data. Patients in this study were not required to have a history of COPD exacerbations to enroll in the study, and thus only 24%-25% of patients had an exacerbation requiring oral/ systemic steroids or antibiotics. Furthermore, patients were required to be withdrawn if they experienced a COPD exacerbation; therefore, no effect on rate of exacerbations could be determined.
Conclusion
The results of the present study indicate that UMEC/VI 125/25 μg and UMEC/VI 62.5/25 μg are beneficial for the once-daily, maintenance bronchodilator treatment of airflow obstruction in Asian patients with moderate -very severe COPD, consistent with studies in predominantly Western populations. The safety profile for UMEC/VI was also comparable to previous studies, and no new safety concerns were identified in this patient population.
enhanced by determination of the score change necessary to achieve a clinically-meaningful improvement in quality of life. 5 The SGRQ contains 76 items grouped into three domains (symptoms, activity, and impacts). The domain score is calculated as the sum of the weighted scores for the nonmissing items within each domain, divided by the maximum possible score for those non-missing items and multiplied by 100. The SGRQ total score is calculated as the sum of the weighted scores from all 76 items, divided by the maximum possible score for the SGRQ, multiplied by 100. A lower SGRQ score indicates better health status. The minimum clinically-important difference for the SGRQ is a -4-unit difference. 5 The SGRQ was self-completed by subjects prior to spirometry at Visits 2, 4, 6, and 8.
COPD assessment test (CaT)
The CAT is a subject-completed instrument designed to provide a simple and reliable measure of health status in COPD. The CAT was designed to measure overall COPD-related health status for the assessment and long-term follow-up of individual subjects. The instrument consists of 8 items, each formatted as a semantic 6-point differential scale. 6 The CAT was completed independently and without supervision by all subjects at Visits 2, 4, 6, and 8. The CAT was administered before any other study procedures were performed (including concurrent medication assessment or AE assessment, etc).
COPD-related healthcare resource utilization assessment
All unscheduled COPD-related visits to a physician's office, urgent care facility, or emergency department, and COPDrelated hospitalizations were recorded on the COPD-related healthcare resource use assessment worksheet within the subject's diary, by the subject. At Visits 2 through 9 or at the Early Withdrawal Visit, the resource utilization worksheet completed by the subject to record all health care contacts since the last visit, was reviewed by the investigator (or designee). The investigator (or designee) asked the subject Ipratropium bromide or theophylline was permitted, provided that the subject was on a stable dose from Screening (Visit 1) and remained on the stable dose throughout the study; however, ipratropium bromide must have been withheld for 4 hours; theophylline must have been withheld for 12 hours prior to and during each clinic visit. Use of study provided salbutamol was permitted during the study, except during the 4-hour period prior to spirometry testing. Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β 2 -agonist.
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Efficacy and safety of UMEC/VI in Asian patients with COPD if any of the health care contacts recorded on the worksheets were due to COPD exacerbation. The investigator could refer to his/her records to verify or supplement information given by the subject if necessary. If any unscheduled health care contact was due to a COPD exacerbation, then the COPD exacerbation section of the electronic case report form was completed.
